In a Fierce Healthcare Industry Voices article, Kevin Lowell examines how the new Congress could shape the next phase of healthcare fraud enforcement and oversight, pointing to potential scrutiny of Medicare Advantage, private equity, vertical integration, and drug pricing. He also discusses how congressional oversight can amplify Justice Department enforcement and whistleblower activity. For companies and investors, Lowell emphasizes the importance of understanding where risks reside, rigorously testing controls in areas of rapid growth and high reimbursement, and addressing potential problems early.